- 全部删除
- 您的购物车当前为空
Sotiburafusp alfa为一双特异性融合蛋白,由人源化VEGFR-1胞外结构域片段经101GGSGGSGGSGGSGGS115肽链与人源化IgG1-kappa 抗PD-L1重链变体L352>A、L353>A的N端(116-564)连接而成。该化合物同时具备血管生成抑制作用。
Sotiburafusp alfa为一双特异性融合蛋白,由人源化VEGFR-1胞外结构域片段经101GGSGGSGGSGGSGGS115肽链与人源化IgG1-kappa 抗PD-L1重链变体L352>A、L353>A的N端(116-564)连接而成。该化合物同时具备血管生成抑制作用。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
5 mg | 待询 | 待询 | |
50 mg | 待询 | 待询 |
Sotiburafusp alfa 相关产品
产品描述 | Sotiburafusp alfa is a humanized bispecific fusion protein comprising a VEGFR-1 extracellular domain fragment (129-228, 1-100 in the current sequence) connected through a 101 GGSGGSGGSGGSGGS 115 peptide linker to the N-terminus (116-564) of a humanized IgG1-kappa anti-human PD-L1 heavy chain with L352>A and L353>A mutations. Additionally, sotiburafusp alfa functions as an angiogenesis inhibitor [1]. |
CAS No. | 2637466-37-4 |
存储 | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。
评论内容